Kadar serum "high density lipoproten cholesterol".(HDL-C) yang rendah merupakan prediktor yang hut untuk terjadinya penyakit jantung koroner (ptX). poa" populasi laki-taki dalam penelitian Framingham diperkirakan terdapat I lVa orang diantaranya yang -mempinyai kadar HDL-C i"ndoh taio dan kira-kira 30Vo penderita dislipidemia mempunyai kadar HDL-C < 35 mg/dl ftipàalihalipoproteinemia), Di samping itu sampai saat ini masih terdapat ketidakpastian mengenai pengelolaan penderila tersebut.
on a large number of patients in Indonesia. We conducted a suruey in 13 cities in Indonesia to evaluate the prevalence o.f hypoalph-atipoproteinemia among dyslipidemic patients and the impact of treatment with lipid modification drugs on achieving target Éia ,t noL-'c 35 mg/dl o, ^ori in routine clinical practice. A total number of 1420 dyslipidemia patients (mean age 50 years, male 5gvo)ïere included.ând analyzed in this report. The overall prevalence of hypoatphatipoproteinemia in our smdy was 35.4vo and it was correlated with the risk livel of the patients; 2 L9vo among low ri ith < 2 othcr risk factor), i9'6vo in high risk group (> 2 other riskfactors) and-44.3% in patients with CHb. After the prevalence decreased to I2Vo, 20Vo and 7AC" in lo* risk, high risk and CHD patienti respectively. The magnitude of HDL-C changes correlated inversely with base-line HDL' C and it was higheit (59Vo) in the lowest HDL-C group (< 25 m7/dt) and the least change (23Vo) was found in group with the highest HDL-C tevet (i45 mg/dl). Only 46% of patients with low HDL-C value at baseline achieved normal HDL-C level after Ûeatment. In conclusion, the prevalence of Iâw HDi-b in dyslipidemia patients was high especially in high nsk group and in CHD patients. The majority of patients with low HDL-C at base-line could not reach the target level for HDL 
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